NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6616.50 16.00 (0.24%)

33.53% Gain from 52W Low

353.3K NSE+BSE Volume

NSE 09 Jan, 2026 3:31 PM (IST)

175,647.3

Market Cap

Market Runner Up

Beta 1Year

Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

07 Jun 2020

6616.50

0.24%

4Q miss estimates; outlook remains positive

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

However, DIVI is well placed to benefit from the CRAMS opportunity due to its strong chemistry skillset as We reduce our earnings estimate by 8%/3% for FY20/FY21E to factor in the COVID led headwinds on the business over the near term. We reduce our earnings estimate by 8%/3% for FY20/FY21 to factor in the delay We expect 25% earnings CAGR over FY20-22E, led by increased business prospects from custom synthesis as well as the generics segment. We continue to value DIVI at 26x 12-month forward earnings to arrive at price target of INR2,245. However, outlook remains intact in terms of opportunities post the We reduce our earnings estimate by 8%/3% for FY20/FY21E to factor in the COVID- 19 led headwinds on the business over the near term. We value DIVI at 26x 12- month forward earnings to arrive at a price target of INR2,245.

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

06 Jun 2020

6616.50

0.24%

Divi's Labs (REDUCE): Q4 disappoints downgrade to REDUCE

Sell: Divi's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Divi's Labs (DIVI) saw a steep 19% EBITDA miss as high gross margins (+200bps QoQ) were negated by staff/SGA cost, leading to subpar Q4 operating margins.

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

20 Apr 2020

6616.50

0.24%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

05 Feb 2020

6616.50

0.24%

Backward integration benefits offset by higher opex related to compliance

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

5 February 2020 DIVI is almost at the end of significant capacity expansion worth INR17b to cater to the increasing generics business and innovators increased outsourcing. Lower Nutraceutical sales impacted DIVIs 3QFY20 performance; however, we believe that the company is well positioned to benefit from the CRAMS opportunity over the next 4-5 years. We reduce our EPS estimate by 3%/2% for FY20/FY21E, primarily to factor in the reduction in Nutraceutical sales and the higher opex related to compliance. 3QFY20 sales grew a marginal 2.7% YoY to INR14b (v/s est. Gross margin shrank 440bp YoY to 60.8%, largely due to inferior product mix and higher raw material cost. EBITDA margin contracted at lower rate of 380bp YoY to 35.4%.

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

06 Nov 2019

6616.50

0.24%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

The custom synthesis (CS) business (42% of FY19 revenues) is a margin accretive business but at times lumpy as it depends on offtake from customers (global top 20 big pharma). However, this business has shown a good recovery on account of an improved business environment. Strong R&D; capabilities and India cost arbitrage along with IP adherence are some legacy strengths, which will drive incremental assignments from MNCs. We...

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

06 Nov 2019

6616.50

0.24%

Divi s Lab: Lower margins on account of product mix

Sell: Divi's Laboratories Ltd.

Recommendation Target

Karvy

Divis Lab s Net revenues increased by 9.2 percent YoY to Rs 14.45 bn, which ishigher than our estimates.

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

05 Nov 2019

6616.50

0.24%

Divi's Labs (ADD): Good Q2 beat; FY20 margin guidance cut is negative

Buy: Divi's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Overall Revenue/EBITDA were 13% ahead of our estimates but largely in-line with consensus.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

05 Nov 2019

6616.50

0.24%

Sales impressive, higher RM cost hurts margins

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

the product mix with a shift toward generics (59% v/s 57% YoY) and increased RM cost led to gross margin contraction of 390bp YoY to 59%. DIVI incurred non-recurring operational expense of INR200m related to power & fuel, consultancy and other regulatory costs. Adjusting for this, the EBITDA margin shrank 410bp YoY to 35.3% (our estimate: 34.2%). Accordingly, EBITDA declined 2% YoY to INR5.1b (our estimate: INR4.6b). DIVI had a forex gain of INR132m for the quarter. Adjusting for the same, PAT was down marginally by 1% YoY to INR3.6b (our estimate: INR3.4b). For 1HFY20, sales/...

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

04 Sep 2019

6616.50

0.24%

Initiating Coverage:Divis Lab.

Buy: Divi's Laboratories Ltd.

Target

Axis Direct

Uptrend in capital expenditure; Strong order visibility: Divi's will incur huge capital expenditure on new block at Unit 1 and Unit 2, with total capex of Rs1,700Cr; We initiate coverage on Divi's Laboratories with a BUY rating and target price of Rs1,900.